Item 5.05 Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics.
[Not that the Medarex's ownership in IDM is large enough to warrant much posting on what goes on in that company, but I thought this was a rather strange notice. Evidently there is not enough work at IDM to keep the CEO busy].
On June 6, 2008, the Board of Directors (the "Board") of IDM Pharma, Inc. (the "Company") approved a waiver of certain provisions of the Company's Code of Conduct and Business Ethics, including the provisions relating to conflicts of interest and corporate opportunities, to allow Timothy P. Walbert, President, Chief Executive Officer and a member of the Board to serve as President and Chief Executive Officer of Horizon Therapeutics, Inc., a private biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief, while continuing to serve as the Company's President, Chief Executive Officer and a member of the Board. |
